- Home
- DPRO vs MBRX Comparison
DPRO vs MBRX Comparison
Compare DPRO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- MBRX
- Stock Information
- Founded
- DPRO 1998
- MBRX 2015
- Country
- DPRO Canada
- MBRX United States
- Employees
- DPRO N/A
- MBRX N/A
- Industry
- DPRO Aerospace
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- DPRO Industrials
- MBRX Health Care
- Exchange
- DPRO Nasdaq
- MBRX Nasdaq
- Market Cap
- DPRO 13.0M
- MBRX 11.3M
- IPO Year
- DPRO N/A
- MBRX 2016
- Fundamental
- Price
- DPRO $2.81
- MBRX $1.06
- Analyst Decision
- DPRO Strong Buy
- MBRX Strong Buy
- Analyst Count
- DPRO 2
- MBRX 2
- Target Price
- DPRO $7.00
- MBRX $6.00
- AVG Volume (30 Days)
- DPRO 78.0K
- MBRX 333.2K
- Earning Date
- DPRO 05-13-2025
- MBRX 05-09-2025
- Dividend Yield
- DPRO N/A
- MBRX N/A
- EPS Growth
- DPRO N/A
- MBRX N/A
- EPS
- DPRO N/A
- MBRX N/A
- Revenue
- DPRO $4,559,961.00
- MBRX N/A
- Revenue This Year
- DPRO $94.01
- MBRX N/A
- Revenue Next Year
- DPRO $95.14
- MBRX N/A
- P/E Ratio
- DPRO N/A
- MBRX N/A
- Revenue Growth
- DPRO 0.10
- MBRX N/A
- 52 Week Low
- DPRO $1.55
- MBRX $0.40
- 52 Week High
- DPRO $9.13
- MBRX $5.47
- Technical
- Relative Strength Index (RSI)
- DPRO 56.44
- MBRX 55.10
- Support Level
- DPRO $2.52
- MBRX $0.80
- Resistance Level
- DPRO $2.75
- MBRX $1.11
- Average True Range (ATR)
- DPRO 0.26
- MBRX 0.10
- MACD
- DPRO 0.06
- MBRX 0.04
- Stochastic Oscillator
- DPRO 86.91
- MBRX 88.24
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.